Search Results
Found 5 results
510(k) Data Aggregation
(88 days)
Ziostation2
• This application software is image processing application software available for installation onto customer-owned hardware. This application software can be networked to provide for sharing of resources.
• This application software receives medical image data (CT, MRI, Ultrasound, Digital X-ray, X-ray Angiography, PET, SPECT, Nuclear Medicine, Secondary Capture, Mammography, X-ray Radiofluoroscopic image, and RT Image) from modalities or image archives such as PACS through network or media, and provides for the viewing, quantification, manipulation, communication, printing and management of medical images.
• This application software is intended only for use by trained medical professionals to supplement generally accepted methods of interpreting radiological images.
Ziostation2 is a basic DICOM image management system to further aid clinicians in their analysis of anatomy, physiology and pathology. Universal functions such as data retrieval, storage, management, querying and listing, and output are handled by the basic Ziostation2 software. Various imaging tools and techniques can be invoked to process images from the following image types: CT, MRI, Ultrasound, Digital X-ray, X-ray Angiography, PET, SPECT, Nuclear Medicine, Secondary Capture, Mammography, X-ray Radiofluoroscopic image, RT Image.
CT Dual kV is a new image processing tool of Ziostation2
The added capabilities provided by this additional image processing tool for use with CT DICOM compliant images are:
Generating and manipulating further images using volume data of two different tube voltage CT scans:
- O Blend image
- Subtraction image
- 0 Virtual non-contrast image
- lodine distribution map
- O 2-Material decomposition image
The provided text is a 510(k) Summary for the Ziostation2 device. It describes the device, its indications for use, and its substantial equivalence to predicate devices. However, the document does not contain specific details about acceptance criteria, device performance metrics, the studies conducted (including sample sizes, ground truth establishment, expert qualifications, or adjudication methods), or any mention of MRMC comparative effectiveness studies or standalone performance evaluations.
Therefore, I cannot provide the requested information based solely on the given text. The text only mentions "integration testing/verification testing" and "regression testing" without elaborating on their specifics or results against defined acceptance criteria.
Ask a specific question about this device
(88 days)
Ziostation2
• This application is image processing application software available for installation onto customer-owned hardware. This application software can be networked to provide for sharing of resources.
• This application software receives medical image data (CT, MRI, Ultrasound, Digital X-ray, X-ray Angiography, PET, SPECT, Nuclear Medicine, Secondary Capture, Mammography, X-ray Radiofluoroscopic image, and RT Image) from modalities or image archives such as PACS through network or media, and provides for the viewing, quantification, manipulation, communication, printing and management of medical images.
•This application software is intended only for use by trained medical professionals to supplement generally accepted methods of interpreting radiological images.
• Lossy compressed mammographic images and digitized film screen images must not be reviewed for primary image interpretations. Mammographic images may only be interpreted using a monitor whose characteristics are approved by the regulatory agency governing the market within which this application is being offered.
Ziostation2 is a basic DICOM image management system to further aid clinicians in their analysis of anatomy, physiology and pathology. Universal functions such as data retrieval, storage, management, querying and listing, and output are handled by the basic Ziostation2 software. Various imaging tools and techniques can be invoked to process images from the following image types: CT, MRI, Ultrasound, Digital X-ray, X-ray Angiography, PET, SPECT, Nuclear Medicine, Secondary Capture, Mammography, X-ray Radiofluoroscopic image, RT Image.
The Ziostation2 is an image processing application software for viewing, quantifying, manipulating, communicating, printing, and managing medical images from various modalities. The 510(k) summary (K181892) indicates that several new functionalities and enhancements were added to the Ziostation2, building upon the features of the previously cleared Ziostation2 (K151212) and other predicate devices.
Here's an analysis of the acceptance criteria and study information provided:
1. A table of acceptance criteria and the reported device performance
The provided text does not explicitly state specific acceptance criteria or quantitative performance metrics for the Ziostation2 software itself. Instead, the document focuses on demonstrating substantial equivalence to predicate devices for its new functionalities and enhancements. The acceptance criteria appear to be based on the functional similarity and safety of the new features compared to already legally marketed devices.
However, based on the text, we can infer that the general "acceptance criterion" is that the new functionalities (LAA analysis, Lung Lobes, Virtual Bronchoscopy, CT Lung Resection Planning, MR Myocardial T1 Mapping) perform similarly to their counterparts in the predicate devices and do not introduce new safety or effectiveness concerns.
Feature/Functionality | Acceptance Criterion (Inferred) | Reported Device Performance (as per 510(k) Summary) |
---|---|---|
Overall Ziostation2 (K151212 aspects) | No significant functional differences from the already cleared Ziostation2 (K151212). Improvements in workflow and usability are acceptable as long as core functionality is maintained. | "With respect to the already-cleared intended use of Ziostation2, no significant functional differences exist between Ziostation2 and SE K151212. Certain improvements in workflow and usability have been implemented." |
LAA analysis (Goddard) | "Adding Goddard score classification" should function similarly to the legally marketed feature in SYNAPSE 3D LUNG AND ABDOMEN ANALYSIS (K130542) and other LAA analysis features cleared in CT PULMONARY ANALYSIS (K130552). | "LAA analysis (Goddard) is adding Goddard score classification to Ziostation2. The feature of Goddard score classification is legally marketed in SYNAPSE 3D LUNG AND ABDOMEN ANALYSIS K130542. Other features are previously cleared in CT PULMONARY ANALYSIS K130552 including LAA analysis." |
Lung Lobes | "Adding lung lobes extraction" should function similarly to the legally marketed feature in SYNAPSE 3D LUNG AND ABDOMEN ANALYSIS (K130542) and other features cleared in CT PULMONARY ANALYSIS (K130552). | "Lung Lobes is adding lung lobes extraction to Ziostation2. The feature of lung lobes extraction is legally marketed in SYNAPSE 3D LUNG AND ABDOMEN ANALYSIS K130542. Other features are previously cleared in CT PULMONARY ANALYSIS K130552." |
Advanced MPR Batch | Workflow enhancement should result in no significant functional differences from SE K151212. | "Advanced MPR Batch is a workflow enhancement. No significant functional differences exist between SE K151212." |
Virtual Bronchoscopy | The new functionality for "showing the route to the desired target" and "showing Virtual Bronchoscopy" should operate similarly to features legally marketed in SYNAPSE 3D LUNG AND ABDOMEN ANALYSIS (K112051) and LUNGPOINT PLANNING AND VIRTUAL BRONCHOSCOPIC NAVIGATION (VBN) SOFTWARE. It should not communicate with real Bronchoscopes. | "Virtual Bronchoscopy is a new functionality added to Ziostation2. The feature of showing the route to the desired target and showing Virtual Bronchoscopy is legally marketed in SYNAPSE 3D LUNG AND ABDOMEN ANALYSIS K112051 and LUNGPOINT PLANNING AND VIRTUAL BRONCHOSCOPIC NAVIGATION (VBN) SOFTWARE. Other features are previously cleared in SE K151212 and CT PULMONARY ANALYSIS K130552. Virtual Bronchoscopy does not communicate with real Bronchoscope." |
CT Lung Resection Planning | Features for "extracting bronchi and lung lobes, extracting lesions and providing the proposal for lung resection" should function similarly to legally marketed features in IQQA-BODYIMAGING SOFTWARE (K141745) and SYNAPSE 3D LUNG AND ABDOMEN ANALYSIS (K130542). Other lung analysis features should align with CT PULMONARY ANALYSIS (K130552). | "CT Lung Resection Planning is a new functionality added to Ziostation2. The feature of extracting bronchi and lung lobes, extracting lesions and providing the proposal for lung resection are legally marketed in IQQA-BODYIMAGING SOFTWARE K141745 and SYNAPSE 3D LUNG AND ABDOMEN ANALYSIS K130542. Some other lung analysis features are previously cleared in CT PULMONARY ANALYSIS K130552." |
MR Myocardial T1 Mapping | New functionality for "analysis of myocardium MR T1 mapping" should align with legally marketed features in SYNGO MR B17 (K082427), MR-CT VVA (K140587), and ACHIEVA, INTERA AND PANORAMA 1.0T, RELEASE 2.5 (K063559). It should focus on post-process analysis and not provide image scanning. | "MR Myocardial T1 Mapping is a new functionality added to Ziostation2, providing analysis of myocardium MR T1 mapping which is legally marketed in SYNGO MR B17 K082427, MR-CT VVA K140587 and ACHIEVA, INTERA AND PANORAMA 1.0T, RELEASE 2.5 K063559. MR Myocardial T1 Mapping provides post process analysis and does not provide image scanning." |
General Software Performance | Successful integration, verification, and regression testing, with identified hazards addressed by risk management. | "The Ziostation2 software package successfully completed integration testing/verification testing prior to validation. Regression testing was also performed on all functionality present on Ziostation2 prior to release. In addition, potential hazards have been addressed by the Ziosoft Risk Management process." |
2. Sample size used for the test set and the data provenance
The document does not specify a sample size for any test set or the data provenance (e.g., country of origin, retrospective/prospective). The submission relies on establishing substantial equivalence to predicate devices, implying that testing focused on confirming functional similarity and safety, rather than a separate clinical performance study with a distinct test set.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
The document does not mention the number or qualifications of experts used to establish ground truth for a test set. This type of information is typically part of a clinical performance study, which is not described here.
4. Adjudication method for the test set
The document does not describe an adjudication method for a test set. As no specific clinical test set is elaborated upon, neither is an adjudication method.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
The document does not mention a multi-reader multi-case (MRMC) comparative effectiveness study. There is no indication of an assessment of human readers' improvement with or without AI assistance. The submission is for an image processing application, which may include AI components, but a specific MRMC study is not detailed.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
The document does not provide details about a standalone (algorithm-only) performance study. The device is an "image processing application software" intended for "trained medical professionals to supplement generally accepted methods of interpreting radiological images," implying a human-in-the-loop context.
7. The type of ground truth used
The document does not explicitly state the type of ground truth used. Given the nature of a 510(k) summary focused on substantial equivalence to predicate devices across various image processing functions, the "ground truth" would likely be implied by the established and accepted performance of the predicate devices themselves, or by standard clinical and radiological interpretation methods. It does not mention pathology or outcomes data as explicitly used for a test set's ground truth.
8. The sample size for the training set
The document does not provide any information regarding the sample size for a training set. This information would typically be relevant for machine learning or AI components, but it is not detailed in this submission.
9. How the ground truth for the training set was established
The document does not describe how ground truth for any training set was established. Similar to point 8, this information is absent.
Ask a specific question about this device
(182 days)
Ziostation2
Ziostation2 is an image processing application software available for installation onto customer owned hardware. This application software can be networked to provide for sharing of resources.
This application software receives medical images from modalities (mage scanning devices such as CT) or image archives such as PACS through network or media and provides for the viewing, quantification, manipulation, communication, printing, and management of medical images.
This application software is intended for use by trained medical professionals to supplement generally accepted methods of interpreting radiological images.
Lossy compressed mammographic images and digitized film screen images must not be reviewed for primary image interpretations. Mammographic images may only be interpreted using a monitor whose characteristics are approved by the regulatory agency governing the market within which Ziostation2 is being offered.
Note: The clinician retains the ultimate responsibility for making the proper diagnosis based on standard radiological practices and visual comparison of the separate, unprocessed images. Ziostation2 is a tool to be used in support of those standard practices and visual comparisons.
ZIOSTATION2 is a basic DICOM image management system to further aid clinicians in their analysis of anatomy, physiology and pathology. Universal functions such as data retrieval, storage, management, querying and listing, and output are handled by the basic Ziostation2 software. Various imaging tools and techniques can be invoked to process images from the following image types: CT, MRI, Ultrasound, Digital X-ray X-ray Angiography, PET, SPECT, NM, SC, Mammography, X-ray Radiofluoroscopic image, RT Image.
The provided text is a 510(k) premarket notification for the Ziostation2, an image processing application software. It focuses on establishing substantial equivalence to existing predicate devices rather than directly presenting explicit acceptance criteria and a detailed study proving device performance against those criteria in a typical clinical performance study format.
However, based on the information provided, we can infer some aspects relevant to your request, especially concerning the "Testing Summary" section.
Here's an analysis based on your questions, extracting what's available and noting what is not explicitly stated in the document:
1. A table of acceptance criteria and the reported device performance
The document does not provide a table of acceptance criteria with corresponding performance metrics (e.g., sensitivity, specificity, accuracy) for the Ziostation2 for specific clinical tasks. The submission focuses on demonstrating substantial equivalence to predicate devices for various image processing functionalities.
The "Testing Summary" states: "The ZIOSTATION2 software package successfully completed integration testing/verification testing prior to Beta validation. Regression testing was also performed on all functionality present on Ziostation. Software Beta testing/validation was successfully completed prior to final testing and release. In addition, potential hazards have been addressed by the Qi Imaging Risk Management process."
This statement confirms that internal testing was performed, but it lacks specific quantitative acceptance criteria and their corresponding results. The acceptance criteria for these internal tests would likely be related to software functionality, accuracy of calculations (e.g., volume, perfusion parameters), visualization correctness, data integrity, and system stability, demonstrating that the new features perform as intended and comparably to the predicate devices. However, these specific criteria and results are not detailed in this public document.
2. Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective)
This information is not explicitly stated in the provided text. The document refers to "integration testing/verification testing" and "Software Beta testing/validation," which would have used some form of test data, but the sample size, provenance, or type of data (e.g., real patient data, synthetic data, specific types of scans) are not disclosed. Given the nature of a 510(k) for an image processing system, it's probable that DICOM datasets were used, but details are absent.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g., radiologist with 10 years of experience)
This information is not explicitly stated in the provided text. For a device like Ziostation2, which is an image processing application, ground truth for verification testing would likely involve validation against known phantom measurements or expert measurements performed on clinical images, but the details of such expert involvement are not provided.
4. Adjudication method (e.g., 2+1, 3+1, none) for the test set
This information is not explicitly stated in the provided text.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
A multi-reader multi-case (MRMC) comparative effectiveness study is not mentioned in the provided text. The document focuses on showing substantial equivalence of the software's processing and visualization capabilities to those of predicate devices, not on the impact of the device on human reader performance in a controlled study. The device is intended "to supplement generally accepted methods of interpreting radiological images," implying it's a tool, not an AI for diagnosis.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
While the "Testing Summary" mentions "integration testing/verification testing," "regression testing," and "Software Beta testing/validation," these are described as internal software tests. It's highly probable these included "standalone" evaluations of the algorithms for their intended functions (e.g., accuracy of measurements, correct rendering of images, proper application of filters). However, specific metrics and results of such standalone performance (e.g., a standalone AUC for a diagnostic task) are not provided, as the device is not presented as an AI diagnostic algorithm, but rather an image processing and visualization tool.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
The type of ground truth used for the internal testing (integration, verification, beta testing) is not explicitly stated. Given the functionalities of Ziostation2 (e.g., CT Coronary Analysis, CT Colon Analysis, CT Perfusion Analysis, MR Tractography), ground truth could involve:
- Known phantom data: for quantitative measurements (e.g., volumes, distances).
- Expert measurements/annotations: on clinical images for comparison with the software's automated or semi-automated tools.
- Previous gold standard software outputs: especially for regression testing against the predecessor Ziostation.
- Pathology or follow-up outcomes data: less likely for general image processing tools, but could be relevant for specific modules if they had a diagnostic claim, which is not the primary focus here.
8. The sample size for the training set
This information is not applicable or not explicitly stated. Ziostation2 is described as an "image processing application software," and its features are discussed in terms of "workflow enhancements" and equivalency to existing functionalities (e.g., data reconstruction, vessel labeling, measurement, display tools). There is no indication that this product is a machine learning or AI model trained on a specific dataset that would require a "training set" in the conventional sense of AI/ML development. Its functionality seems to be based on established algorithms in image processing.
9. How the ground truth for the training set was established
This information is not applicable or not explicitly stated, for the same reasons as in point 8.
Ask a specific question about this device
(64 days)
CT BRAIN PERFUSION FOR ZIOSTATION
Ziostation is an image processing workstation software package designed to run on standard PC hardware. It provides for the viewing, quantification, manipulation, printing, and management of medical images. It is intended for use by trained medical professionals to aid in their reading and review of such data. In addition, Ziostation has the following indication:
The CT Brain Perfusion for Ziostation option is an image analysis software package providing additional image processing capabilities to the basic Ziostation device. The CT Brain Perfusion Option is intended for post-processing based on dynamic CT images continuously acquired during the injection of contrast, for the visualization of apparent blood flow in brain tissue and pictorial illustration of perfusion-related parameters to aid in the assessment of the type and extent of cerebral perfusion disturbances.
CT Brain Perfusion for Ziostation is an add-on software feature designed to provide a color map of cerebral blood flow and pictorial illustration of perfusion-related parameters obtained on CT images of the brain. This software is designed to work within the currently cleared Ziostation image management device.
The provided text does not contain detailed information about specific acceptance criteria, comprehensive study results, sample sizes for test or training sets, ground truth establishment methods, expert qualifications, or adjudication methods. The document is primarily a 510(k) summary for a "CT Brain Perfusion for Ziostation" software, describing its intended use, predicate device, and confirming substantial equivalence.
Here's an analysis of what can be extracted and what information is missing based on your request:
1. Table of Acceptance Criteria and Reported Device Performance:
The document explicitly states: "All devices met the required specifications for the completed tests." However, it does not detail what those specifications or acceptance criteria were, nor does it provide specific metrics for device performance beyond this general statement.
Acceptance Criteria | Reported Device Performance |
---|---|
Not specified | Met all required specifications for completed tests. |
2. Sample size used for the test set and the data provenance:
- Sample Size for Test Set: Not specified. The document mentions "1000" under the "Testing Summary" section, but it's unclear if this refers to the number of tests performed, the size of a dataset, or something else entirely. It does not explicitly state it as the test set sample size.
- Data Provenance (country of origin, retrospective/prospective): Not specified.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Number of Experts: Not specified.
- Qualifications of Experts: Not specified.
4. Adjudication method for the test set:
- Adjudication method: Not specified.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, and the effect size of how much human readers improve with AI vs without AI assistance:
- The document does not mention an MRMC comparative effectiveness study. The device is described as an "image analysis software package providing additional image processing capabilities" and "pictorial illustration...to aid in the assessment," suggesting it's a tool for professionals rather than a standalone diagnostic or a direct comparison of human performance with vs. without AI. No effect size is provided.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- The document does not explicitly state whether a standalone performance study was conducted. Given its description as "image analysis software package providing additional image processing capabilities" and intended "to aid in their reading and review," it implies human-in-the-loop use.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- Type of Ground Truth: Not specified.
8. The sample size for the training set:
- Sample Size for Training Set: Not specified.
9. How the ground truth for the training set was established:
- Ground Truth Establishment for Training Set: Not specified.
In summary, the provided 510(k) summary is very high-level regarding testing and validation. It states that all specifications were met but does not offer the granular detail about the study methodology, data characteristics, or performance metrics that your questions are looking for.
Ask a specific question about this device
(60 days)
ZIOSTATION
ZIOSTATION is an image processing workstation software package designed to run on standard PC hardware. The required hardware consists of standard 'off-the-shelf' computer components. It receives image data from standard modalities (medical image scanning devices) or from image archives. It provides for the viewing, quantification, manipulation, communication, printing, and management of medical images. It can be used as a just a workstation or as a client-server within a network. It is intended for use by trained medical imaging professionals to aid in their reading and review of such data.
Lossy compressed mammographic images and digitized film screen images must not be reviewed for primary image interpretations. Mammograpic images may only be interpreted using an FDA approved monitor that offers at least 5 MPixel resolution and meets other technical specifications reviewed and accepted by FDA.
ZIOSTATION is a software-only imaging workstation that installs on one or more of a customer's standard PCs and integrates with a customer's 'off the shelf' PC-based computer components to provide viewing, quantification, manipulation, communication, printing, and management capabilities for medical images. It provides access to both local and centralized (networked) image data.
ZIOSTATION can acquire and work with image data from multiple DICOM-compliant modalities and image archives. It provides querying and listing based on user-selected criteria. It provides for multiple types of 2D and 3D image displays. It provides interactive menus and tools for image manipulation and measurement. ZIOSTATION provides workflow enhancement and optional specialist tools for clinical applications.
ZIOSTATION uses only lossless compression for images used for diagnostic purposes. It does use lossy compression when exporting to JPEG and AVI files, but its labeling indicates that those files are not to be used for clinical evaluations.
The ZIOSTATION is a PACS system that has not conducted any clinical studies to establish specific acceptance criteria or performance metrics directly from the provided text. The document states that the device has been "thoroughly tested by Ziosoft in accordance with their software development and validation procedures" and "independently evaluated by trained physicians specializing in medical imaging disciplines." However, no specific acceptance criteria or performance data from these evaluations are presented in the document.
Instead, the submission relies on demonstrating substantial equivalence to a legally marketed predicate device, the Barco Voxar 3D Enterprise (K061326). The "acceptance criteria" in this context are implicitly met by showing that ZIOSTATION's features and intended use are essentially identical to the predicate device, and that it does not introduce any new safety or efficacy concerns.
Given the information in the provided text, the specific details requested for a study proving device adherence to acceptance criteria (such as sample size, data provenance, ground truth establishment, expert qualifications, adjudication methods, MRMC studies, or standalone performance) are not available. The document focuses on regulatory clearance through substantial equivalence rather than explicit performance evaluation against predefined numerical criteria.
Therefore, the table of acceptance criteria and reported device performance cannot be filled with numerical values, and many of the questions regarding study design cannot be answered from this document.
Here's a breakdown of what can and cannot be answered based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
Based on the provided document, no specific numerical acceptance criteria or performance metrics are reported for ZIOSTATION. The submission relies on substantial equivalence to a predicate device.
Acceptance Criteria (Not Explicitly Stated - Inferred from Equivalence Claim) | Reported Device Performance (Not Explicitly Stated - Inferred from Equivalence Claim) |
---|---|
Functional Equivalence: Must perform core image processing and management functions similarly to the predicate device. | ZIOSTATION provides identical basic functions (view, quantify, manipulate, communicate, print, and manage medical images) as the predicate device (Voxar 3D Enterprise). |
Technical Equivalence: Must be compatible with standard hardware, DICOM compliant, and offer comparable imaging capabilities (2D, 3D, measurement, segmentation, remote rendering). | ZIOSTATION is compatible with PC/Windows OS, DICOM 3.0, acquires data from multiple sources, offers 2D/3D imaging, measurement tools, segmentation tools, and remote rendering, all "same" as the predicate. |
Clinical Application Equivalence: Must provide comparable optional specialist tools and workflow enhancements for clinical applications. | ZIOSTATION offers "optional specialist tools and workflow enhancements for clinical applications such as coronary, colon, and vessel analysis," which are "same" as the predicate. |
Intended Use Equivalence: Must have the same intended use by trained medical imaging professionals. | ZIOSTATION is "intended for use by trained medical imaging professionals to aid in their reading and review of such data," which is "same" as the predicate. |
Safety and Efficacy: Must not raise new safety or efficacy concerns compared to the predicate. | Ziosoft "demonstrated that ZIOSTATION is safe and effective for its intended use" and "does not raise any new safety or efficacy concerns." |
Interpretation Restrictions: Must adhere to specific restrictions for mammographic image interpretation. | "Lossy compressed mammographic images and digitized film screen images must not be reviewed for primary image interpretations. Mammographic images may only be interpreted using an FDA approved monitor that offers at least 5 MPixel resolution and meets other technical specifications reviewed and accepted by FDA." (This is a condition of use rather than a performance metric.) |
2. Sample size used for the test set and the data provenance
- Not specified. The document mentions internal testing and independent evaluation by physicians but provides no details on sample size or data provenance (e.g., country of origin, retrospective/prospective nature).
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
- Not specified. The document vaguely states "independently evaluated by trained physicians specializing in medical imaging disciplines" but does not quantify the number of experts or their specific qualifications (e.g., years of experience, subspecialty). No explicit "ground truth" establishment process for a test set is described.
4. Adjudication method (e.g., 2+1, 3+1, none) for the test set
- Not specified. No details on adjudication methods for any evaluation are provided.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- No indication of an MRMC study. The ZIOSTATION is an image processing workstation, not specifically an AI-driven diagnostic aid that would typically undergo such a study to measure reader improvement. The document does not describe AI functionality or a reader improvement study.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Not applicable/Not specified as a standalone algorithm. ZIOSTATION is described as an "image processing workstation software package" intended for use by "trained medical imaging professionals to aid in their reading and review." It is not presented as a standalone diagnostic algorithm.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
- Not specified. Since no specific performance study with a test set is detailed, the type of ground truth used is not mentioned. The primary argument is substantial equivalence to a predicate, not performance against a ground truth dataset.
8. The sample size for the training set
- Not applicable/Not specified. ZIOSTATION is an image processing and visualization system, not an AI/machine learning model where a distinct "training set" would typically be referenced for model development. The document does not mention any machine learning components requiring a training set.
9. How the ground truth for the training set was established
- Not applicable/Not specified. As there's no mention of a training set, the method of establishing ground truth for it is also not discussed.
Ask a specific question about this device
Page 1 of 1